Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: No
Stroke 35:804-805,806, Tong,D.C. &Becker,K.J., 2004
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: Yes
Stroke 35:803-804,806, Furlan,A.J., 2004
Antithrombotic and Interventional Treatment Options in Cardioembolic Transient Ischaemic Attack and Ischaemic Stroke
JNNP 78:14-24, McCabe,D.J.H. &Rakhit,R.D., 2007
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004
Patent Foramen Ovale and Brain Infarct:Echocardiographic Predictors, Recurrence, and Prevention
Stroke 25:782-786, Hanna,J.P.,et al, 1994
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
Intracranial Atherosclerosis
Lancet 383:984-998, Qureshi, A. & Caplan, L.R., 2014
Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013
Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures
NEJM 368:2113-2124, Baron, T.,et al, 2013
Treatment of Atherosclerotic Intracranial Arterial Stenosis
Stroke 40:2257-2261, Turan,T.N.,et al, 2009